Turk

This feels like a very positive development for #AVCT.

#AVCT sitting right at the Weekly 200MA. “How fast?” The market has no real concept of time. This is a weekly chart, so my initial target is around 110p over the coming weeks, not days. Patience pays, though many of you probably know that even better than I do. If price can reclaim and hold above the 200MA, I suspect the move could accelerate quickly.

Dose Doxorubicin safely for half a decade without a single serious cardiac event and you’re considered interesting. Dose Exatecan safely whilst extending its release for 5 weeks and you’re more than interesting. You’re a threat. #AVCT know their USP. Feet up. Wait. Reap.

@coughlin582 #AVCT

As noted, we will be communicating any updates at the event via announcements on that morning and the video recording of the presentations will be made available as soon as editing is complete following the event. We look forward to next week.

We are delighted to share the next chapter of #AVCT next week. Very much looking forward to seeing all of our guests in London in T-minus 7 days #LetsDoThis #HopeWithoutCompromise #FOCUSOnTheWin

Primed. To. Run. #AVCT

Early next week the Q3W arm will receive their 2nd dose. The PK vitals be taken 24 hrs post 2nd dose. On Tuesday #AVCT will host x2 poster sessions at AACR: AVA6103 & AVA6207. Early the following week, the Q2W arm receives their 3rd dose. The following week is Science Day.

🔥 #AVCT

Retention of 100% of our pipeline remains overwhelmingly in the best interests of #AVCT shareholders, for now. 💰 Delighted to have subscribed to the placing with credit to the team at Zeus for all their efforts. Looking forward to 2026! 🧨

⬇️ Response to the final question at TD Cowan “What do you think is the most under appreciated aspect of Avacta?” = 🔥 Those 2 points + the confidence with which the CEO can deliver the message (due to the supporting data + science) is what will see #AVCT sold for a massive sum.

Avacta has today published new data which demonstrates the more favorable delivery and advantages of the proprietary pre|CISION platform, compared to a marketed antibody drug conjugate (ADC). avacta.com/avactas-precis… #AVCT

It’s been highly impressive to watch the speed at which @coughlin582 and her team have expedited AVA6103 and AVA6207 since I joined the board of #AVCT a little over 6 months ago. The pre|CISION technology which sits behind these drugs is nothing short of groundbreaking.

#LondonLifeSciences Week. Avacta Tx thrilled to be selected as the Company to Watch using AI as an accelerator in drug development. So proud of our team and everything we have accomplished. #AVCT #HopeWithoutCompromise linkedin.com/posts/christin…

#AVCT breakout time?👀

@Onil_coder SEND

ChatGPT-4o is insanely powerful. But only few people know how to use it. That's why I created a list of 12000 prompts that you can use to automate all your tasks for free. Like + comment "SEND" and I will DM you the file. (Must be following me to receive it)

#AVCT 👀

@MylesMcNulty @avacta 🫡

It is straightforward to watch yesterday's presentation by @avacta #AVCT and understand that it is making truly revolutionary advances in oncology. I am more convinced than ever that the pre|CISION platform's peptide-drug conjugates will largely displace antibody-drug conjugates and go on to dominate the >$350bn per annum global oncology market for decades to come. We are only 4 months into what I believe will be one of the all-time great turnarounds for an LSE-listed stock. Avacta's share price is (only!) +135% in that period - but the picture is becoming clearer for many now. Expecting daily volumes to continue to increase and the SP to challenge 100p before Christmas, regardless of any commercial news flow. That said, I really think Big Pharma will make a move soon, whether that's for an initial licensing deal or an outright takeover attempt.

“The pre|CISION® platform has been validated by compelling clinical data” “Single molecule” “Significant reduction in off-target toxicities” ADC technology has an interesting challenger. #Targets25 #AACR #AVCT

AVA6000 is different: it releases doxorubicin in the tumour microenvironment, targeting cancer cells and the stromal “support system.” Its effect is less about shrinkage and more about disease control. Unlike ADCs, tied to a single antigen and focused on shrinkage. #AVCT #ESMO25

@coughlin582 @FierceBiotech @FiercePharma

Thrilled to be at #ESMO25 for the Faridox Ph Ia presentation. Moving at the speed of light here! Poster session was jammed and our own #AVCT AVA6K had quite a day. #LetsDoThis #CancerGoingDown #preCISEDelivery #HopeWithoutCompromise